Second CD19-targeted CAR T-cell infusion for R/R B-cell malignancies

Second CD19-targeted CAR T-cell infusion for R/R B-cell malignanciesПодробнее

CD19 Targeted CAR T-cell Therapy in LBCLПодробнее

Efficacy of bispecific CD19/CD22 CAR T-cells in B-cell malignanciesПодробнее

Long-term trial supports CD19-targeted CAR T cells for relapsed/refractory CLLПодробнее

Anti-CD20/19 CAR-T cell therapy in r/r B-cell malignanciesПодробнее

Findings for CD19-Targeted CAR T Cells in Combination With Ibrutinib in CLLПодробнее

Current research on CD19 targeted CAR T-cells in relapsed B-cell ALLПодробнее

Role of CD19 CAR T Cells in Second Line Large B Cell LymphomaПодробнее

Repeat infusions of CD19 CAR-TПодробнее

Efficacy and safety of CD19-targeted CAR T-cells for relapsed/refractory ALLПодробнее

Dr. Park on Using CD19-Targeted CAR T Cells as Treatment for ALLПодробнее

Anti-CD22 CAR T-cell therapy for ALL: trial update, utility for salvage and CD19 statusПодробнее

Evaluating post-infusion CAR-Treg cells to identify patients resistant to CD19 CAR-T therapyПодробнее

CD19-Targeted CAR T-Cell Therapy in Managing DLBCLПодробнее

CD19 CAR T-cells for adultsПодробнее

Bispecific CAR T-cell therapy: combining anti-CD19 and CD22 CAR T-cellsПодробнее

Dr. Brentjens on CD19-Targeted T Cells in CLL and ALLПодробнее

Evaluating dual-targeting CD19/22 CAR-T cells in patients with R/R ALLПодробнее

Phase I study of CD22-targeted CAR-T therapy in patients with CD19-negative B-ALLПодробнее